Link Therapeutics

Link Therapeutics

Private
KyotoHealthcare & Life Scienceshttps://www.link-therapeutics.com/

Last Round

Series B

Jul 30, 2025

Total Funding Raised

$7.84M

Company Overview

Link Therapeutics is a biotechnology company that develops medical devices and pharmaceuticals for autoimmune diseases by targeting pathogenic autoantibodies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

CAR-T therapylogic-gated CAR-TAND-gate CAR-Tcell therapysolid tumor therapydual antigen targetingcancer immunotherapyon-target, off-tumor toxicitynext-generation CAR-Tengineered T-cellsprecision oncologychimeric antigen receptor T-celltherapeutic platformrenal cell carcinomacolorectal cancer

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Link Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Link Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BJul 30, 2025
Early FundingFeb 28, 2023
SeedDec 12, 2022

Key People

Founding team and executive leadership

Toru Kawamura

President CEO

Executive Team

Link Therapeutics Investors

Notable investors and investment history

InvestorRounds
ITOCHU Technology VenturesSeries B
Kobe University CapitalSeries B
Mitsubishi UFJ CapitalSeries B, Early Funding
Kyoto University Innovation CapitalSeries B, Early Funding, Seed
SMBC Venture CapitalSeries B, Early Funding

Link Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Link Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Link Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersKyoto
Employee Range5
Year Founded2022
Last FundingJul 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.